62 results about "Poly l arginine" patented technology

A therapeutic composition is provided including a polysaccharide or a cationic peptide dissolved in an organic substance. The polysaccharide can be heparin or a derivative of heparin. The cationic peptide can be L-arginine, oligo-L-arginine or poly-L-arginine. The organic substance can be formamide. A method of coating an implantable medical device is also provided, comprising applying the therapeutic composition to the device and allowing the organic substance to evaporate. The device can be a stent.

The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.

The invention provides a double-layer microencapsulation prebiotic and probiotic composition and a preparation method thereof. A microencapsulation protection technology is used; natural polymer sodium alginate, glucose and prebiotics are used as outer wall materials; poly-L-arginine and prebiotics are used as inner wall materials; probiotics and dried skim milk are used as core materials. The specific double-layer microencapsulation structure provides dual protection for unstable probiotics; the influence of external environment and adverse factors (such as light, temperature, humidity, pH and bile) is avoided; the reduction of probiotic activity in the use and storage processes is effectively prevented; the stability, the activity and the effective fix planting rate of the composition are maintained to the greatest degree; the embedding efficiency is high; the embedding effect is good. The double-layer microencapsulation composition has the advantages that the directional controlledrelease effect can be effectively realized; the intestinal flora balance can be effectively reduced; the body immunity is improved.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.

The invention relates to a preparation method and application of a multifunctional nano siRNA (Small Interfering Ribonucleic Acid) carrier system which integrates tumor targeting, pH sensitivity, visualization and the like. The core of the siRNA nano carrier system consists of cadmium telluride quantum dots. A nano carrier shell consists of a tumor targeted gene, a 9 poly-l-arginine peptide chain and PEG (Polyethylene Glycol). The siRNA nano carrier is good in biocompatibility, strong in tumor targeting and high in cell transfection efficiency, and has the characteristics of high quantum yield, strong optical stability, lossless in-position real-time monitoring and the like, so that the system is suitable for being used as a nano transmission system for in vivo gene therapy of tumors.

The invention provides a serial cell-penetrating peptide modified tumor targeted and tumor penetrated nano drug delivery system capable of simultaneously identifying an integrin receptor and a transmembrane protein receptor, wherein the serial cell-penetrating peptide is mainly formed by connecting a DGR polypeptide fragment covalently at the C-tail end of polyarginine of the cell-penetrating peptide. The polypeptide not only can selectively identify two highly expressed receptors on the surfaces of the tumor cells, but also can be efficiently mediated into the cells. The nano drug delivery system mainly consists of a nano carrier, a drug and a lipid-polyethylene glycol-serial cell-penetrating peptide ligand interstitial compound and is a potential tumor targeted treatment carrier.

The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.

A nanoparticle, a chemical structure, and a treatment method for treating a patient having a disorder. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to or encapsulated in the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The treatment method administers a therapeutic effective amount of the nanoparticle or chemical structure to the patient to treat the disorder. The disorder may be a vascular disorder, pulmonary hypertension, cardiac insufficiency, a neurological disorder, and combinations thereof.

A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.

The invention provides a delivery molecule and a nanoparticle, a preparation method and application. The delivery molecule comprises cell penetrating peptide, poly-L-arginine is linked to the C or N end of the cell penetrating peptide, the delivery molecule can combine with siRNA and other nucleotides, protein and DNA to form a nanoparticle with a diameter of 600nm, the delivery molecule can deliver siRNA into cells, and release siRNA to play a therapeutic role. The invention indicates that the delivery molecule can deliver transferred substances into cells or animal bodies both on the cell and animal level and release the transferred substances to play a part, and the delivery molecule is non-toxic and has high delivery efficiency.

The invention provides a reduced sensitive type polymer with the effect of arginine membrane penetration as well as a preparation method of the reduced sensitive type polymer. The polymer can self-assemble in an aqueous medium to form micelle of a shell-core structure; the polymer contains a poly-L-arginine structure, so that the speed that the polymer penetrates through a cell membrane to enter cancer cells is increased; meanwhile, the polymer contains a disulfide bond, so that the polymer can be degraded by relatively high reduction potential energy in cancer cells. The invention further provides application of the reduced sensitive type polymer with the effect of arginine membrane penetration as a drug carrier. After being gathered at tumor tissue through the enhanced permeability and retention effect, the carrier can quickly enter the cancer cells, so that bioavailability and the treatment effect of the drug can be improved.

A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a polycationic polymer ionically bonded to one or more polyanionic Glycosaminoglycans (GAGs), wherein the polycationic polymer is chitosan, methylated chitosan, poly L-Lysine, or poly L-Arginine.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to telmisartan enteric-coated tablets and a preparation method thereof. The telmisartan enteric-coated tablets are each composed of a tablet core, an isolating layer and an enteric coating. The table cores are composed of, by weight, 20-40 parts of telmisartan, 8-20 parts of poly-L-arginine, 10-60 parts ofmannitol, 60-160 parts of microcrystalline celluloses, 3-9 parts of povidone and 0.5-3 parts of magnesium stearate. Poly-L-arginine is adopted for alkalizing telmisartan, in this way, the solublenessof telmisartan can be improved remarkably, and moisture absorption is reduced; meanwhile, mannitol is added, in this way, powder with good fluidity can be obtained, and the prepared tablets are high in dissolution rate and good in stability; common rapid-disintegration oral administration preparations are prepared into the enteric-coated tables, in this way, it can be avoided that the preparationsdisintegrate in gastric acid, and telmisartan is separated out, the bioavailability of telmisartan is improved remarkably, and application prospects are good.

The invention relates to a method for preparing a pH-responsive nanofluidic diode based on nanopores modified by polyarginine and polyglutamic acid layer by layer. The inner surfaces of the nanoporesare modified by adopting a layer-by-layer polyelectrolyte electrostatic adsorption method. The method comprises the following steps of firstly, carrying out chemical etching on a PET film to obtain asingle conical polyarginine modified nanopore, and enabling the nanopore modified by the polyarginine molecule to be subjected to pH action to obtain the nanofluidic diode with anion selectivity. Polyglutamic acid molecules have a large number of carboxyl groups, polyarginine and polyglutamic acid can be modified on a polyarginine molecular layer through an electrostatic adsorption method, and nanopores modified by polyarginine and polyglutamic acid layer by layer are obtained. The nanopores modified by polyarginine and polyglutamic acid layer by layer are subjected to pH action to obtain thenanofluidic diode with cation selectivity.

The invention aims to overcome defects that bio-macromolecular nucleic acid and polypeptide medicines degrade easily in bodies and can hardly reach target cells and provides a nano preparation for combined transportation of nucleic acids and polypeptides and a preparation method. According to the nano preparation, multifunctional cationic polypeptides and cationic liposomes/nucleic acid non-viral carriers which are safe to human bodies are adopted to coat polypeptide medicines and nucleic acid medicines simultaneously to form nanoparticles, and bio-macromolecular medicine carriers capable of treating diseases through combination of the polypeptides and the nucleic acids are prepared. The cationic liposomes and the polypeptides are mixed and then assembled with the nucleic acid medicines under the electrostatic effect, the nanoparticles with positive charges on surfaces are formed, and nano target particles with negative charges on surfaces are further formed under the electrostatic effect by covering hyaluronic acids with hydrogen bonds. The nano preparation has the advantages that the polypeptide medicines and the nucleic acid medicines are loaded simultaneously, the polypeptide medicines are released continuously through breakage of degradable bonds between the polypeptide medicines and poly-L-arginine, and the nucleic acids are released effectively through disassembly of the carriers.

The invention discloses a degradable organic and inorganic composite nano-particle capable of realizing anti-tumor treatment, and a preparation method thereof. The inner part of the particle is Fe3O4,the middle layer of the particle is gamma-PGA (polyglycolic acid) and Poly-l-arginine (PA), and the outer layer is a golden shell. The size of the particle is about 200nm, and the particle has biodegradability. The preparation method for the degradable organic and inorganic composite nano-particle comprises the following steps: through a gamma-PGA, Fe<2+> and Fe<3+> coprecipitation method, preparing high-dispersion magnetic Fe3O4 nano-particles; then, through a static electricity mutual function, adsorbing doxorubicin hydrochloride (DOX.HCl) and PA to the surface of the particle; finally, carrying out in-situ reduction of chloroauric acid on the surface of the PA to prepare the gamma-PGA-Fe3O4-DOX-PA@Au(PFDR-Au) composite nano-particles. The method has the advantages of simpleness in operation, short time consumption, small material consumption, no organic solvent, moderate and controllable synthesis condition and high reproducibility. The nano-particle has biodegradability and good biocompatibility, Adriamycin can be released under the condition of photo-thermal stimulation and micro acid, and a tumor growth inhibition effect is obvious.

A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof.

The invention discloses an analysis method for detecting impurities in aspartate ornithine and belongs to the field of analytical chemistry. The analysis method comprises the following steps: by usingliquid chromatography, under the conditions that an amino bonded silica gel filling agent, namely Thermo APS-2 of 4.6 mm*250 mm*5 [mu]m, is adopted, 0.1 mol/L monopotassium phosphate buffer solution-acetonitrile (35:65) is used as a mobile phase A, 0.1 mol/L monopotassium phosphate buffer solution-acetonitrile (50: 50) is used as a mobile phase B, a detection wavelength is 200 nm, a flowing speedis 1.0 ml/minute, and a column temperature is 30 DEG C, performing gradient elution, and performing analysis. By adopting the technical scheme, impurities such as 3-amino-2-piperidone, di-poly-l-arginine and an alpha-aspartate biopolymer and an aspartate condensation compound can be rapidly and accurately qualitatively and quantitatively analyzed, a good separation degree can be achieved, a relatively low detection limit and quantitative limit can be achieved, a relatively wide linear range can be achieved, the contents of different impurities can be relatively accurately calculated, and technical support can be provided for further monitoring and studying impurities in the aspartate ornithine.

A both transcrption and transfer controlled, alpha-fetoprotein enhanced, and epidermal growth factor receptor mediated liver cancer target gene transfer carrier is composed of alpha-fetoprotein mediated exogenous DNA, ligand oligopeptide, polycation polypeptide and endocytic glubule release oligopeptide. It can suppress the growth of liver cancer cells.